Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Sorafenib is a small molecule that blocks tumor proliferation by targeting the activity of multi-kinases for the treatment of advanced hepatocellular carcinoma (HCC). Increasing sorafenib resistance following long-term treatment is frequently encountered. Mechanisms underlying sorafenib resistance r...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yung-Sheng, Su, Chien-Wei, Chen, San-Chi, Chen, Yen-Ying, Liang, Yuh-Jin, Wu, Jaw-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870465/
https://www.ncbi.nlm.nih.gov/pubmed/35203285
http://dx.doi.org/10.3390/cells11040634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870465/
https://www.ncbi.nlm.nih.gov/pubmed/35203285
http://dx.doi.org/10.3390/cells11040634

Ejemplares similares